CompletedPhase 1NCT00003427
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
Studying Adenocarcinoma of the anal canal
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Nancy E. Kemeny, MDMemorial Sloan Kettering Cancer Center
- Intervention
- irinotecan hydrochloride(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1998 – 2002
Study locations (1)
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003427 on ClinicalTrials.govOther trials for Adenocarcinoma of the anal canal
Additional recruiting or active studies for the same condition.